Valine

Valine

SCHEMBL2383315

CC(C)[C@H](N)C(=O)O.CCCCCCl

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.58
TSHR P16473 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GRIK1 P39086 2/20 0.41
GRIK2 Q13002 2/20 0.41
SLC1A2 P43004 2/20 0.41
SLC1A1 P43005 2/20 0.41
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
ACE2 Q9BYF1 1/20 0.39
GPR84 Q9NQS5 3/20 0.38
FFAR1 O14842 1/20 0.38
SLC1A3 P43003 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 1/20 0.37
TP53 P04637 1/20 0.37
LCK P06239 1/20 0.37
PPARD Q03181 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL27206170 1.00 SLC7A5 (0.58) SLC7A5TSHRALDH1A1GRIK1GRIK2
Valine SCHEMBL4045692 0.90 SLC7A5 (0.71) SLC7A5GRIK1GRIK2SLC1A2SLC1A1
Dodecane SCHEMBL28109673 0.88 SLC7A5 (0.68) SLC7A5TSHRALDH1A1GRIK1GRIK2
Valine SCHEMBL11005807 0.88 SLC7A5 (0.68) SLC7A5TSHRALDH1A1GRIK1GRIK2
Threonine SCHEMBL28254028 0.87 ALDH1A1 (0.43) SLC7A5TSHRALDH1A1GRIK1GRIK2
Alanine SCHEMBL28014257 0.86 TSHR (0.50) TSHRALDH1A1GRIK1GRIK2SLC1A2
Isoleucine SCHEMBL28819073 0.85 ALDH1A1 (0.41) SLC7A5TSHRALDH1A1GRIK1GRIK2
Alanine SCHEMBL28481821 0.84 TSHR (0.48) TSHRALDH1A1GRIK1GRIK2SLC1A2
Valine SCHEMBL28133161 0.83 SLC7A5 (0.75) SLC7A5SLC1A2SLC1A1DPP4SLC1A3
Valine SCHEMBL28133160 0.83 SLC7A5 (0.75) SLC7A5SLC1A2SLC1A1DPP4SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547653-B1 N-CARBOMETHOXY-N-METHOXY-(2-CHLOROMETHYL)-ANILINES, THEIR PREPARATION AND THEIR USE AS PRECURSORS FOR PREPARING 2-(PYRAZOL-3'-YLOXYMETHYLENE)-ANILIDES BASF SE (DE) 2015-01-28 EP claimed
CN-102858735-B N-carbomethoxy-n-methoxy-(2-chloromethyl)-anilines, their preparation and their use as precursors for preparing 2-(pyrazol-3'-yloxymethylene)-anilides BASF SE 2014-12-10 CN claimed
EP-2547653-A1 N-CARBOMETHOXY-N-METHOXY-(2-CHLOROMETHYL)-ANILINES, THEIR PREPARATION AND THEIR USE AS PRECURSORS FOR PREPARING 2-(PYRAZOL-3'-YLOXYMETHYLENE)-ANILIDES BASF SE (DE) 2013-01-23 EP claimed
CN-102858735-A N-carbomethoxy-n-methoxy-(2-chloromethyl)-anilines, their preparation and their use as precursors for preparing 2-(pyrazol-3'-yloxymethylene)-anilides BASF SE 2013-01-02 CN claimed
WO-2011113884-A1 N-CARBOMETHOXY-N-METHOXY-(2-CHLOROMETHYL)-ANILINES, THEIR PREPARATION AND THEIR USE AS PRECURSORS FOR PREPARING 2-(PYRAZOL-3'-YLOXYMETHYLENE)-ANILIDES BASF SE (DE) 2011-09-22 WO claimed
EP-4247800-A1 N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2023-09-27 EP disclosed
US-20230286930-A1 N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-09-14 US disclosed
CN-111620896-B Preparation method of tetra-coordinated N, N-chelated diaryl borate compound with 8-aminoquinoline derivative as bidentate ligand 石河子大学 2023-04-07 CN disclosed
CN-111620896-B Preparation method of tetra-coordinated N, N-chelated diaryl borate compound with 8-aminoquinoline derivative as bidentate ligand 石河子大学 2023-04-07 CN disclosed
CN-115210218-A Pesticidally active cyclic amine compounds 先正达农作物保护股份公司 2022-10-18 CN disclosed
WO-2022106589-A1 N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2022-05-27 WO disclosed
CN-111620896-A Preparation method of tetra-coordinated N, N-chelated diaryl borate compound with 8-aminoquinoline derivative as bidentate ligand 石河子大学 2020-09-04 CN disclosed
US-6329530-B1 REACTING ALKYL VINYL ETHER WITH PHOSGENE OR PHOSGENE DERIVATIVE TO FORM ACYL CHLORIDE DERIVATIVE; DEHYDROCHLORIANTING TO FORM 3-ALKOXYACRYLOYL CHLORIDE COMPOUND; REACTING WITH ALKYLHYDRAZINE BASF AKTIENGESELLSCHAFT (DE) 2001-12-11 US disclosed
EP-0769512-B1 Process for preparing polycondensation polymers using haloiminium salts as condensation agents MITSUI CHEMICALS INC (JP) 2001-07-18 EP disclosed
CN-1220667-A Morphinane derivatives and medicinal use thereof TORAY INDUSTRIES (JP) 1999-06-23 CN disclosed
EP-0769512-A2 Process for preparing polycondensation polymers MITSUI TOATSU CHEMICALS, INC. (JP) 1997-04-23 EP disclosed
EP-0213450-B1 Aminoacyl derivatives of 4,9-dihydro-10H-pyrido[3,2-b]-thieno-[3,2-e][1,4]diazepinone and of 4,9-dihydro-10H-pyrido[3,2-b]-thieno[3,4-e][1,4]diazepinone, their preparation and pharmaceutical compositions containing them DOMPE' FARMACEUTICI S.p.A. (IT) 1992-01-08 EP disclosed
CN-87105898-A N-(sProcess and intermediates for the preparation of -3-alkylheptanoyl -D-r-glutamyl -glycyl -D-alanyl 1988-03-09 CN disclosed
US-4659707-A ANTIULCER, ANTISECRETORY, ANTIMUSCARINIC AND/OR ANTISPASMODIC AGENTS DOMPE' FARMACEUTICI S.P.A. (IT) 1987-04-21 US disclosed
EP-0213450-A2 Aminoacyl derivatives of 4,9-dihydro-10H-pyrido[3,2-b]-thieno-[3,2-e][1,4]diazepinone and of 4,9-dihydro-10H-pyrido[3,2-b]-thieno[3,4-e][1,4]diazepinone, their preparation and pharmaceutical compositions containing them DOMPE' FARMACEUTICI S.p.A. (IT) 1987-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286930-A1 N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, CYP2E1, CYP7A1 SLC7A5 2183/4885TSHR 1534/4885ALDH1A1 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.